Payment overview · 2025
General Payments
$521.26
24 reported records · 13 companies
Healthcare provider profile · identity verified
Bryan Anthony Picou, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NATCHITOCHES, LA · NPI 1174969133
Verified facts
What the public records show
CMS Open Payments records show Bryan Anthony Picou, M.D. received $521.26 in general payments during 2025 across 24 reported records.
Xeris Pharmaceuticals, Inc. accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $97.55 | 18.7% | 5 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $92.95 | 17.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.88 | 10.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $50.87 | 9.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.07 | 9.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.79 | 6.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.64 | 6.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.14 | 4.1% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $19.54 | 3.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.48 | 3.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.10 | 3.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.90 | 3.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.35 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $521.26 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $92.95 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $92.95 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $59.80 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $50.87 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $49.07 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $37.75 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.64 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL FOAM Normalized: aquacel foam |
Device | ConvaTec Inc. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 144 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 101 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 152 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
152 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
144 | 23 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 727 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 381 | 111 |
| Hydrochlorothiazide | Hydrochlorothiazide | 314 | 76 |
| Metformin Hcl | Metformin Hcl | 309 | 81 |
| Gabapentin | Gabapentin | 289 | 68 |
| Meloxicam | Meloxicam | 262 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 242 | 46 |
| Montelukast Sodium | Montelukast Sodium | 224 | 45 |
| Losartan Potassium | Losartan Potassium | 208 | 54 |
| Lisinopril | Lisinopril | 205 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 44 |
| Omeprazole | Omeprazole | 170 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 46 |
| Simvastatin | Simvastatin | 164 | 47 |
| Sertraline Hcl | Sertraline Hcl | 160 | 34 |
| Famotidine | Famotidine | 159 | 40 |
| Jardiance | Empagliflozin | 152 | 33 |
| Carvedilol | Carvedilol | 144 | 26 |
| Eliquis | Apixaban | 144 | 23 |
| Trazodone Hcl | Trazodone Hcl | 119 | 24 |
| Potassium Chloride | Potassium Chloride | 117 | 40 |
| Furosemide | Furosemide | 108 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 34 |
| Farxiga | Dapagliflozin Propanediol | 101 | 26 |
| Alendronate Sodium | Alendronate Sodium | 96 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 92 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 24 |
| Metformin Hcl Er | Metformin Hcl | 88 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 20 |
| Ozempic | Semaglutide | 83 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 22 |
| Celecoxib | Celecoxib | 77 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 13 |
| Donepezil Hcl | Donepezil Hcl | 71 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 18 |
| Doxepin Hcl | Doxepin Hcl | 66 | 11 |
| Levetiracetam | Levetiracetam | 64 | 15 |
| Rexulti | Brexpiprazole | 64 | suppressed |
| Allopurinol | Allopurinol | 62 | 14 |
| Myrbetriq | Mirabegron | 62 | suppressed |
| Spironolactone | Spironolactone | 61 | 13 |
| Prednisone | Prednisone | 58 | 40 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 56 | suppressed |
| Trulicity | Dulaglutide | 56 | 13 |
| Ezetimibe | Ezetimibe | 51 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 18 |
| Primidone | Primidone | 50 | suppressed |
| Entresto | Sacubitril/Valsartan | 48 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 48 | 44 |
| Baclofen | Baclofen | 47 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 46 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 31 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | 13 |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Sucralfate | Sucralfate | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 27 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Methocarbamol | Methocarbamol | 33 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Nabumetone | Nabumetone | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 12 |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Anastrozole | Anastrozole | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 22 |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 22 | 22 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Pregabalin | Pregabalin | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Hyzaar | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $521.26 · 24 records | Xeris Pharmaceuticals, Inc. | ABRYSVO, AQUACEL FOAM, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, GEMTESA, GVOKE HYPOPEN, JARDIANCE, KEVEYIS, Kerecis GraftGuide, Kerecis SurgiClose, Kerendia, NURTEC ODT, NUZYRA, Ozempic, PREVNAR 20, XHANCE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error